NCT00633490

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Phase 1 Study of Apatinib as an Inhibitor of Angiogenesis

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), so it can inhibit tumor angiogenesis. This phase I study aims to determine the drug's toxicity and to find a dose level to be used in a phase II study in solid tumor patients.

Detailed description

Apatinib is a tyrosin-inhibitor agent targeting at VEGFR (vasoendothelial growth factor receptor) to inhibit tumor angiogenesis. The anti-angiogenesis effect of apatinib has been viewed in preclinical tests (see protocol). This phase I clinical study is going to evaluate its toxicity and to find an appropriate dose level to be used in a phase II study in heavily treated solid tumor patients.

Conditions

• Tumor

Interventions

Type	Name	Description
DRUG	apatinib	apatinib is a tablet in the form of 250mg and 100mg and 50mg, orally, daily

Timeline

• Start date: 2007-07-01
• Primary completion: 2008-06-01
• Completion: 2008-06-01
• First posted: 2008-03-12
• Last updated: 2008-07-22

Locations

1 site across 1 country: China